• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Breast Cancer Drug Pipeline Update 2014 Product Image

Breast Cancer Drug Pipeline Update 2014

  • Published: March 2014
  • Region: Global
  • Bioseeker

Breast cancer is the leading cause of cancer-related mortality among women worldwide. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic setting, the overall survival remains below five years.
There are today 383 companies plus partners developing 528 drugs targeting breast cancer in development. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 207 drugs. Breast Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 309 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 301 out of the 304 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 67 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How READ MORE >

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos